secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001140361-24-000830
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q2 Revenue $79.1M, Per-Share Loss $0.72; Restructuring Manufacturing; SVP Resigns
--------------------------------------------------------------------------------

- Net sales $79.1M (up 2.7% pro-forma); GAAP net loss $29.0M or $0.72 per share; adjusted loss $0.05 per share
- Initiated restructuring to fully outsource manufacturing; expects $15M annualized cost savings by FY27
- David D. Helsel, SVP of Global Operations and R&D, resigns effective Jan 12, 2024 (no disagreement)
- Completed enrollment in APEX-AV trial for acute intermediate-risk pulmonary embolism using AlphaVac F18
- Revised FY2024 guidance: net sales $320-$325M, gross margin 49-51%, adjusted loss per share $0.35-$0.42

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/0001140361-24-000830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/ef20017917_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-000830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer